恒瑞医药(600276.SH)：注射用甲苯磺酸瑞马唑仑的药品上市许可申请获受理

Core Viewpoint - Heng Rui Medicine has received acceptance notification from the National Medical Products Administration for its drug application of injectable remimazolam tosylate, indicating progress in its market entry [1] Group 1: Product Information - Remimazolam tosylate is a short-acting GABAa receptor agonist belonging to the benzodiazepine class, which produces sedative and anesthetic effects by inhibiting neuronal activity [1] - The advantages of remimazolam tosylate include rapid onset, short recovery time, and minimal impact on respiratory and cardiovascular systems [1] Group 2: Market Context - The drug was developed by PAION AG and has been approved for sale in Japan, the United States, and China in 2020 [1] - The global sales for remimazolam tosylate are projected to reach approximately $59.22 million in 2024 [1] Group 3: R&D Investment - The cumulative research and development investment for injectable remimazolam tosylate has reached approximately 184 million yuan [1]